Status and phase
Conditions
Treatments
About
This is a phase I/II, open-Label, dose-Escalation and dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 (an Anti-CCR8 mAb) as a Single Agent or in combination with Toripalimab in Advanced Solid Tumours.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
392 participants in 4 patient groups
Loading...
Central trial contact
Paul kong; Mengmeng LIU
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal